Koehl GE - Search Results

1

Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model.

Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK, Dahlke MH. Inoue S, et al. Among authors: koehl ge. Transplantation. 2006 Jun 15;81(11):1589-95. doi: 10.1097/01.tp.0000209919.90630.7b. Transplantation. 2006. PMID: 16770249

2

A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis.

Guba M, Cernaianu G, Koehl G, Geissler EK, Jauch KW, Anthuber M, Falk W, Steinbauer M. Guba M, et al. Cancer Res. 2001 Jul 15;61(14):5575-9. Cancer Res. 2001. PMID: 11454710

3

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Guba M, et al. Nat Med. 2002 Feb;8(2):128-35. doi: 10.1038/nm0202-128. Nat Med. 2002. PMID: 11821896

4

Rapamycin treatment at immunosuppressive doses affects tumor blood vessel circulation.

Koehl G, Guba M, Seeliger H, Steinbauer M, Anthuber M, Jauch KW, Geissler EK. Koehl G, et al. Transplant Proc. 2003 Sep;35(6):2135-6. doi: 10.1016/s0041-1345(03)00745-0. Transplant Proc. 2003. PMID: 14529865 No abstract available.

5

Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy.

Seeliger H, Guba M, Koehl GE, Doenecke A, Steinbauer M, Bruns CJ, Wagner C, Frank E, Jauch KW, Geissler EK. Seeliger H, et al. Among authors: koehl ge. Clin Cancer Res. 2004 Mar 1;10(5):1843-52. doi: 10.1158/1078-0432.ccr-1176-3. Clin Cancer Res. 2004. PMID: 15014039

6

Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer.

Bruns CJ, Koehl GE, Guba M, Yezhelyev M, Steinbauer M, Seeliger H, Schwend A, Hoehn A, Jauch KW, Geissler EK. Bruns CJ, et al. Among authors: koehl ge. Clin Cancer Res. 2004 Mar 15;10(6):2109-19. doi: 10.1158/1078-0432.ccr-03-0502. Clin Cancer Res. 2004. PMID: 15041732

7

Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice.

Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, Steinbauer M, Graeb C, Schlitt HJ, Jauch KW, Geissler EK. Koehl GE, et al. Transplantation. 2004 May 15;77(9):1319-26. doi: 10.1097/00007890-200405150-00002. Transplantation. 2004. PMID: 15167584

8

Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer.

Guba M, Koehl GE, Neppl E, Doenecke A, Steinbauer M, Schlitt HJ, Jauch KW, Geissler EK. Guba M, et al. Among authors: koehl ge. Transpl Int. 2005 Jan;18(1):89-94. doi: 10.1111/j.1432-2277.2004.00026.x. Transpl Int. 2005. PMID: 15612989 Free article.

9

Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells.

Meyer S, Hafner C, Guba M, Flegel S, Geissler EK, Becker B, Koehl GE, Orsó E, Landthaler M, Vogt T. Meyer S, et al. Among authors: koehl ge. Int J Oncol. 2005 Nov;27(5):1197-206. Int J Oncol. 2005. PMID: 16211213

10

Development of de novo cancer in p53 knock-out mice is dependent on the type of long-term immunosuppression used.

Koehl GE, Gaumann A, Zuelke C, Hoehn A, Hofstaedter F, Schlitt HJ, Geissler EK. Koehl GE, et al. Transplantation. 2006 Sep 27;82(6):741-8. doi: 10.1097/01.tp.0000233852.75162.74. Transplantation. 2006. PMID: 17006319

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

47 results

Search Page

Filters